TEK and pancreatic neuroendocrine tumor: The therapeutic benefit of targeting TIE2+ TAMs was demonstrated using the selective TIE2 inhibitor Rebastinib, which reduced pancreatic neuroendocrine tumor growth and metastasis in mice.